Covid 19 has established a public-private partnership in the pharmaceutical industry through IMI projects, with the assistance of former vaccine competitors such as Sanofi and Glaxo. But the question is whether this new spirit will spread to other areas such as non-communicable diseases? Yes, there has been an increase in the number of people involved in the production of new antibiotics. Today, we have seen the unavoidable rapid adoption of digital technologies in the health care sector.